BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Firazyr icatibant regulatory update

FDA approved Firazyr icatibant from Shire to treat acute attacks of hereditary angioedema (HAE) in adults. The company said Firazyr is the first self-administered subcutaneous treatment approved in the U.S. for acute HAE. Shire launched the product with a wholesale acquisition cost of $6,800 per dose. Shire...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >